FlowCardia today announced it has raised $30 million in Series C financing
FlowCardia, Inc., a medical device company developing endovascular devices for coronary and peripheral chronic total occlusion (CTO) recanalization, today announced it has raised $30 million in Series C financing. Gilde Healthcare Partners led the financing, joined by new investors Life Sciences Partners, Hambrecht & Quist Capital Management LLC and New Science Ventures and existing investors Frazier Healthcare Ventures, JP Morgan Partners and Pappas Ventures. Rockport Venture Partners and Gold Hill Capital also participated in this round.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.